The FDA has approved daraxonrasib for patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC). 1.
AI-powered trial screening helps community oncology practices identify eligible patients locally, widening access beyond ...
The first patient has been dosed in MODeFIRe-1 (NCT07745361), a phase 2 study evaluating MRT-2359 in combination with ...
An exploratory analysis from the SECOMBIT trial showed differences in outcomes based on thymidine kinase activity in ...
The recent FDA approval of iberdomide (Zenbexus) represents more than the approval of a single new drug for ...
The benefit of daraxonrasib in PDAC may be overstated in RASolute 302 due to informative censoring. The RASolute 302 trial (NCT06625320) in pancreatic cancer has received a lot of attention. The study ...
Zanidatamab plus tislelizumab and chemotherapy reduced mortality risk by 28% versus trastuzumab plus chemotherapy, delivering ...
Priority review reflects AZUR-1 meeting its primary end point of meaningful, sustained 12-month cCR in dMMR/MSI-H stage ...
Sustained MRD negativity at 12 months was higher with D-VRd, with similar advantages at 24 and 36 months and a lower rate of ...
Primary endpoint results showed no SSE-FS benefit with radium-223 addition (HR 1.46; 1-sided P=.12), while OS, PFS, and ORR ...
Laila Alkhouli, MD, of Cleveland Children's Clinic outlines critical findings from research evaluating how care teams across ...
As artificial intelligence (AI) becomes more integrated into clinical trial matching, human oversight remains an important ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results